Comparative Pharmacology
Head-to-head clinical analysis: FLAVORED COLESTID versus LOCHOLEST LIGHT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAVORED COLESTID versus LOCHOLEST LIGHT.
FLAVORED COLESTID vs LOCHOLEST LIGHT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Colestid (colestipol) is a bile acid sequestrant. It binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased hepatic conversion of cholesterol to bile acids, thereby lowering serum low-density lipoprotein (LDL) cholesterol levels.
Locholest Light is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and decreased serum LDL cholesterol.
5-30 grams orally daily, divided into 2-4 doses, starting at 5 grams once daily and increasing by 5 grams every 4-7 days as tolerated; taken with meals and mixed with at least 4-8 oz of liquid per dose.
LOCHOLEST LIGHT is not a recognized drug name. No data available.
None Documented
None Documented
Not applicable due to non-absorbable resin; systemic absorption is negligible. Terminal half-life not defined.
Terminal elimination half-life is approximately 19-24 hours; due to enterohepatic recirculation, effective half-life may be extended. Steady state is achieved within 4-6 weeks with continuous dosing.
Primarily fecal as insoluble complex (90-95%); <5% renal as glucuronide conjugate; minimal biliary elimination.
Primarily biliary/fecal (approximately 75% as metabolites, <10% unchanged drug in feces); renal excretion accounts for about 20% of total elimination (mainly as inactive metabolites).
Category C
Category C
Bile Acid Sequestrant
Bile Acid Sequestrant